Somatic activating mutations in KRAS and GNAS are the most prevalent genetic alterations seen in IPMN, with either or both seen in >95% of all IPMNs [3,4]. This evidence concerns the gene GNAS and pancreatic intraductal papillary-mucinous neoplasm.